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Abstract
Background: In a previous study (Goebel et. al, Cancer Genomics Proteomics 16:229-244, 2019), we identified 33
biomarkers for an early stage (I-II) Non-Small Cell Lung Cancer (NSCLC) test with 90% accuracy, 80.3% sensitivity,
and 95.4% specificity. For the current study, we used a narrowed ensemble of 21 biomarkers while retaining similar
accuracy in detecting early stage lung cancer.
Methods: A multiplex platform, 486 human plasma samples, and 21 biomarkers were used to develop and validate
our algorithm which detects early stage NSCLC. The training set consisted of 258 human plasma with 79 Stage I-II
NSCLC samples. The 21 biomarkers with the statistical model (Lung Cancer Detector Test 1, LCDT1) was then
validated using 228 novel samples which included 55 Stage I NSCLC.
Results: The LCDT1 exhibited 95.6% accuracy, 89.1% sensitivity, and 97.7% specificity in detecting Stage I NSCLC on
the blind set. When only NSCLC cancers were analyzed, the specificity increased to 99.1%.
Conclusions: Compared to current approved clinical methods for diagnosing NSCLC, the LCDT1 greatly improves
accuracy while being non-invasive; a simple, cost-effective, early diagnostic blood test should result in expanding
access and increase survival rate.
Keywords: Immunoassay, Early stage lung cancer, Detection, Biomarkers, Proteomics, Diagnostic tests, Non-small
cell lung cancer
Background
Lung cancer is a pervasive disease that is commonly di-
agnosed at a late stage and has a global estimated mor-
tality rate of 84.2% for 2019. The American Cancer
Society predicts about 228,150 new cases and 142,670
deaths for 2019 in the United States. On average, 422
Americans die every day of lung cancer (LC). Non-small
Cell Lung Cancer (NSCLC) accounts for 84% of all LCs,
and exhibits a 5-year survival rate of 23% [1]. However,
if NSCLC is detected at stages I-II, the survival rate sig-
nificantly improves and it may even be cured [2].
NSCLC patients diagnosed at stage I have a 5-year sur-
vival rate between 68 and 92%; at stage II between 53
and 60%; at stage III, it decreases to 26–36%; and for
stage IV detection the survival rate drops precipitously
to 1–10% [1, 2]. Despite significant investment and ad-
vancement in LC research, only 16% of LCs are detected
at the early stages [1].
The research community continues to improve early
LC detection through the use of Computed Tomography
(CT) and Positron Emission Tomography (PET) scans,
improved pulmonary nodule (PN) guideline, biomarkers,
and machine learning algorithms. In our approach, we
combine biomarkers and machine learning. We detect
early stage NSCLC with high sensitivity and specificity
using a simple blood test. Before presenting our results,
we briefly review the state-of-the-art of these
approaches.
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CT scans recommended for diagnosing LC
The US Preventive Service Task Force (USPSTF) recom-
mends that low-dose computed tomography (LDCT)
scans be used as a screening method for LC in high risk
patients age 55–85 with a 30-year smoking history, who
have not quit for more than 15 years. The recommenda-
tion was in part based on the National Lung Screening
Trial (NLST) study which demonstrated that screening
with LDCT reduces LC mortality by 20% compared to
chest x-rays [3, 4]. However, this approach is not ideal.
In the NLST study, a PN was detected in 1 of every 4
subjects that had LDCT scans. Of the 7191 subjects
found to have suspicious nodules on LDCT scans, 88.6%
had a follow-up test (e.g., imaging, 89.8%; biopsy, 1.9%;
and surgery, 4.7%), and only 292 (4.1%) were confirmed
to have LC. Of these 292 cases, 54.1 and 41.1%, turned
out to be Stage I and II, respectively. The LDCT scans
had a false positive rate (FPR) of 96.1% [4]. Obviously,
there is a need for a test with a lower FPR. Deep learning
algorithms show promise to reduce the false positives in
interpreting these images [5].
PET scans increasing in use for LC follow-ups
PET scans have better statistics than LDCT [6]. A multi-
center observational study by Tanner, et al., [7] evaluat-
ing PN management shows an increase in PET scan use
with additional follow-ups of patients with indeterminate
lung nodules. The accuracy rate of PET scans is 74%,
with an overall FPR of 39% (36–55%) and overall false
negative rate (FNR) of 9% (8–10%), depending on node
size. The study concludes that 25% of PNs referred to a
pulmonologist were malignant; 46% had additional sur-
veillance, 33.2% had a biopsy, and 20.4% underwent lung
surgery. About 35% of patients who had surgery had be-
nign masses.
Pulmonary nodule guidelines
Most solitary PNs are detected incidentally by chest radi-
ography and CT scans that were ordered to investigate
other diseases. Approximately 150,000 solitary PNs are de-
tected annually in the United States of America [8].
Recommendations for managing intermediate PNs,
found in PET/CTs using the Lung-RADS [7, 9] or
Fleischner criteria [10], are not always followed. Many
physicians consider other factors, such as age, smoking
status, gender, patient preference, and use their experi-
ence when deciding on follow-up procedures for that pa-
tient’s specific clinical situation. In a multicenter
observational study of 377 patients, Tanner et al., indi-
cated that invasive procedures were performed in 44% of
low risk nodules (< 5% probability of malignancy) [7].
Today, current guidelines for management of lung nod-
ules try to incorporate other factors that may be unique
to a patient [9, 10]. Prospective research on physician
adherence to new guidelines and outcome on performed
PN follow-up procedures will need to be completed.
Evaluating biomarkers to detect LC
There is a growing trend to use genetic and protein bio-
markers for disease diagnosis, prognosis, and the evalu-
ation of treatment efficacy (e.g., Grail, Guardant, Myriad
Genetics) [11, 12]. Biomarkers are defined as ‘any sub-
stance, structure, or process that can be measured in the
body or its products and influence or predict outcome or
disease’ [13]. Thus, a biomarker can be of physical,
chemical, or biological nature, such as measurements of
blood pressure, temperature, inflammatory cytokines
(proteins), genetic (DNA) markers, or metabolites [14].
In this paper, we will limit our discussion to DNA and
protein biomarkers.
DNA biomarkers
DNA biomarkers have been used to assess risk for devel-
oping specific diseases or response to therapy. DNA pro-
vides genetic information of the individual. Nonetheless,
the path from DNA to an observable physical trait (e.g.,
disease) is complex. For instance, somatic mutations in
the TP53, EGFR, and KRAS genes are commonly found
in LC patients [15]; yet, somatic mutations are often due
to increased exposure to carcinogens (e.g., smoking,
radon), environmental factors (e.g., pollution, second-
hand smoke), age, and health history (e.g., chronic
COPD). Inherited mutations following an autosomal
dominant pattern predispose an individual to be at high
risk, but need not always predict the development of LC.
The pattern of inheritance, penetrance, and expressivity
of genetic mutations, in addition to lifestyle, environ-
mental factors, and even ethnicity, are important compo-
nents in assessing cancer risk [16].
Protein biomarkers
In contrast, protein reflects phenotype: the observable
end-trait (e.g., tissue) resulting from the interaction of
genome and the environment [17]. Protein biomarkers
provide quantitative data that can be compared be-
tween a healthy and a diseased individual. Proteomics
has its own challenges. Proteins, like genes, are pleio-
tropic: meaning the same protein markers may con-
tribute to different immune-related pathways for
different diseases. For example, IL-8 is a pleiotropic
cytokine and has also been linked to breast, prostate,
lung, colorectal, and skin cancer [18]. Hence, using a
single biomarker, protein or DNA, would not be suffi-
cient for clinical diagnostic use.
Protein levels can fluctuate due to physiological
stressors (e.g., disease, strenuous exercise) and samples
(i.e., serum, plasma) are sensitive to environmental factors
(i.e., pH, temperature) and degrade faster than DNA.
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Moreover, analytic protein platforms require the use of
antibodies which, in turn, exhibit lot-to-lot variations due
to the idiosyncratic nature of antibodies.
Despite the intricacies, genome and protein bio-
markers, have proven to be essential tools in the discov-
ery of predictive, prognostic, and diagnostic markers in
LC [19–21].
Machine learning in medicine
Advances in computing combined with an increase in
the amount of data collected has enabled the application
of various machine learning techniques, such as Neural
Networks and Random Forests, to tease out complex
and non-linear relationships in data. These methods can
also assist radiologists to interpret x-rays, CAT scans,
PET scans and other diagnostic imaging methods; diag-
nose patients with disease; and may lead to a general im-
provement in patient care [22].
While machine learning methods are powerful, they
have drawbacks. No machine learning method can com-
pensate for poor data (i.e., dirty data). Machine learning
is unable to provide causal information on its own; they
are simply a set of advanced statistical techniques that
can improve our ability to find complex, non-linear rela-
tionships in data [23, 24].
Further, statistical models can be impacted by bias,
human error, sample population, poor technical de-
sign, misapplication, and disparate systems. It is im-
portant that appropriate machine learning techniques
and algorithms are applied to each study, that the data
is collected, cleaned and processed in a consistent
manner, and that bias are scrutinized from all angles
[25].
Our preliminary studies identified protein biomarkers
that may significantly improve our ability to identify
NSCLC so this study was undertaken to prospectively
test that hypothesis.
Methods
This study is a continuation of our previous research
that used 33 biomarkers [11]. Here we reduced the num-
ber of biomarkers to 21, ensured successful transfer of
reagents, and retrained our algorithm.
Study population
This study was performed on biobank plasma samples
from 486 subjects distributed into 5 cohorts (Table 1).
In previous studies, we demonstrated that our method
detected early to late stage NSCLC. In this study, our
focus was to detect stage I-II LC. Therefore, samples
from patients with Stage I-II NSCLC (Table 2) were
used to train the LCDT1 algorithm and, subsequently,
only Stage I NSCLC samples (Table 2) were used in a
blind set to validate clinical efficacy.
Sample collection and handling
Human plasma samples were obtained from five blood
banks: Asterand, BioReclamation, BioSource, Geneticist,
and Proteogenex. All cancer samples were confirmed by
histology. All samples were collected through an IRB ap-
proved protocol (e.g., Protocol #AST-FPB-003, Western
IRB) or a signed Waiver of Consent form. Individuals
under the age of 18 or those who cannot consent for
themselves were not included in the study. Samples were
collected in the United States between 2013 and 2015.
Clinical information such as age, gender, pathology
and stage, race, origin, smoking status, and sample col-
lection dates were obtained. Whole blood samples were
collected in EDTA tubes and stored at − 80 °C according
to the biobank’s protocol. Plasma samples were trans-
ported on dry ice overnight to our sample storage site in
Michigan City, Indiana, USA. Vials were inspected visu-
ally for damage upon receipt and stored at − 80 °C until
analysis.
Table 1 Sample Criteria
Cohort Inclusion Exclusion
All cohort M/F, 18 y/o or older, sample collected in the USA Pregnant, incarcerated, lack of capacity to consent, samples collected
outside of sthe United States
Asthma Smoker or non-smoker Any cancer diagnosis
Non-Smoker Healthy Smokers, any cancer diagnosis
NSCLC,
(Stage I-II)
Stage I-II; smoker or non-smoker Stage III-IV lung cancer
Smoker 10 pack years Any cancer diagnosis
Other
Cancers
Breast, colon-rectal, pancreatic, and prostate cancer, all stages;
smoker or non-smoker
The non-smoker and NSCLC served as negative and positive control for lung cancer, respectively. Asthma sufferer and COPDs were included to test whether the
diagnostic test can differentiate lung cancer from those who may have other respiratory diseases which share similar symptoms. The smokers consisted of high-
risk population for LC who were not diagnosed with any cancer. Other cancers (i.e., breast, prostate, pancreatic, and colon-rectal) were included to ensure that the
diagnostic test was specific to NSCLC
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Multiplexed immunoassay procedure
This study used a custom-made multiplexed immuno-
assay to measure the concentration of 21 biomarkers in
human plasma samples. Sample collection and handling,
and immunoassay procedure are consistent with our
previous study (1, Supplementary Figure 1). Sample pro-
cessing was performed by Eve Technologies Corporation
(Calgary, Alberta, Canada). This assay reagent and for-
mat was validated against the 33-biomarker reagent used
in the previous study [11] to ensure that all biomarkers
performed similarly and maintained its congruity with
the algorithm.
Algorithm and statistical analysis
The algorithm considers duplicate measurements of the
biomarkers from a patient and classifies each measure-
ment as having NSCLC or not having NSCLC. If any of
the measurement is classified as being from a subject
with NSCLC, the subject is classified as having NSCLC.
Since the implicit costs of allowing the disease to pro-
gress without treatment is greater than the cost of a false
negative, the LCDT1 algorithm errs on the side of pre-
dicting that a subject has NSCLC.
A 5-PL curve was used to acquire the calibration
curve. Data was cleaned based on preset criteria of ±20%
coefficient of variation and removal of extrapolated and
out of range data. Median, rather than average, was used
to represent the central tendency of the plasma concen-
trations due to the skewed distributions and outliers.
Normalization of diseased cohorts to healthy cohorts
was examined for pattern recognition. P-values were cal-
culated using T-tests, adjusted using Benjamini-
Hochberg’s method for multiple comparisons [26]. The
AUC was calculated for each biomarker and as a com-
bined set of biomarkers. The ROC curve was used illus-
trate the performance of the model. Excel and R Version
3.4.4 were used for data analysis.
Results
Training set for optimizing the LCDT1 algorithm
In this study, we included the 33-biomarker model to
examine congruity in using a higher set of biomarkers
versus a smaller subset. Table 3 illustrates the algorithm
performance using 33 versus 21 biomarkers are analo-
gous. The LCDT1 algorithm was developed with slight
modifications using a smaller subset of biomarkers from
the 21. This information is proprietary and a patent ap-
plication was filed. Patterns of up and down regulation
of biomarkers were similar to our previous study [11].
The median concentration in LC patients compared to
healthy non-smokers, asthma sufferers, and smokers was
more than 200% higher in SAA (771%), MMP-9 (743%),
IL-8 (535%), CXCL9/MIG (482%), TNFRI (406%), Gro
(331%), MPO (300%), Rantes (274%), Resistin (271%),
TNFRII (266), and MIF (219%). IL-2 and IL-7 showed
greater than a 50% reduction in signal (Table 5).
Validation set performance
A novel blinded sample set of 228 (N = 456) subjects
were processed in duplicate using the LCDT1. Of 228
subjects, 55 were Stage I NSCLC samples (Table 2). Our
proprietary algorithm accurately detected 49 of the 55
Stage I LC samples (Fig. 1). There were 6 positive
Table 2 Sample Distribution
African-American Caucasian Hispanic Total
Training Set
Female 37 69 27 133
Asthma 0 10 1 11
Breast Cancer 0 1 0 1
Colon-Rectal Cancer 0 2 0 2
Non-Smoker 15 17 10 42
NSCLC, (Stage I-II) 10 22 10 42
Pancreatic Cancer 0 2 0 2
Smoker 12 15 6 33
Male 49 53 23 126
Asthma 0 4 0 4
Non-Smoker 18 14 9 41
NSCLC, (Stage I-II) 9 17 10 37
Pancreatic Cancer 0 2 0 2
Smoker 22 16 4 42
Total 86 122 50 258
Validation Set
Female 29 88 18 135
Asthma 0 8 0 8
Breast Cancer 5 35 0 40
Colon-Rectal Cancer 0 3 0 3
Non-Smoker 9 12 9 30
NSCLC, Stage I 6 17 4 27
Pancreatic Cancer 0 2 0 2
Smoker 9 11 5 25
Male 25 51 17 93
Asthma 0 3 0 3
Colon-Rectal Cancer 0 2 0 2
Non-Smoker 7 11 9 27
NSCLC, Stage I 5 18 5 28
Pancreatic Cancer 0 1 0 1
Prostate 3 6 0 9
Smoker 10 10 3 23
Total 54 139 35 228
All samples were collected in the United States and proportionately
distributed between genders. The age range was between 21 and 82 years old
with an average age of 56
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samples that were not detected and 4 negative LC sam-
ples that showed up as positive. The 4 samples that were
false positives consisted of 3 breast cancers and 1 asthma
sufferer (Supplementary Table 1). We were unable to
follow-up with the patients to confirm if the breast can-
cer had metastasized into the lungs [27] or whether the
asthma diagnosis was erroneously reached for an indi-
vidual actually suffering of LC [28].
Algorithm 33 and the LCDT1 exhibit a similar accur-
acy rate of 95.6%, sensitivity of 89.1%, and a specificity
of 97.7% in the validation test (Table 4). When only
NSCLC cancers were analyzed, the specificity of both al-
gorithms improved to 99.1%. This validation shows that
the results are comparable using the 33 markers (from
the previous study) versus the 21 or the LCDT1 markers
(Table 4). Additional biomarkers were unnecessary to
achieve the same clinical performance.
ROC curves and P-values
The Area under the ROC Curve (AUC) is the probability
that an observation with a higher probability of being
positive is positive. In our model, a ‘positive’ means that
the model predicts that the subject has NSCLC. Al-
though the discriminatory power, using AUC, for each
individual biomarker was examined, it was not the deter-
mining factor in our selection process. The ROC/AUC
for Algorithm 33, Algorithm 21, and the LCDT1 are
0.965, 0.960, and 0.966, respectively (Fig. 2a). When only
NSCLC cancers were analyzed, the AUC for each algo-
rithm improved by 0.01 (Fig. 2b). Once more, the P-
values (p < 0.05) imply that several biomarkers are able
to discriminate NSCLC from other pathologies to a
degree (Table 5). These results (e.g., patterns, ROC/
AUC, performance) provide a strong foundation for de-
veloping a clinical diagnostic test for NSCLC.
Discussion
Protein biomarkers have been extensively examined for
diagnostic, prognostic, and therapeutic assessment of
diseases and its treatments. Yet, many lab-developed as-
says never fully mature to penetrate the clinical setting
[29]. Apart from the regulatory hurdles, there are many
factors, such as sample collection, reagent manufactur-
ing, and the acquisition of data, that may cause variabil-
ity of end-results, which affects robustness and
consistency, ~a requisite of any biological test used for
clinical utility [30, 31]. Reducing the number of bio-
markers was an important component of the present
study as decreases complexity and the number of inter-
actions between the antibodies, simplifies reagent pro-
duction, and is more cost-effective [32].
In narrowing our list, the biological justification for
the selection of biomarkers was critical in avoiding nu-
merical quirks that may mask the true driver of a
physiological process [11]. To elaborate, the statistical
model in the previous study was a Random Forest (RF)
model. When an RF model is fit, a measure of the vari-
able’s importance is calculated. In this case, the variables
are the biomarkers. The variable’s importance is defined
as how well, on average, the biomarker increases the dis-
tinction of groups in the model (in our case NSCLC and
not-NSCLC). Here, the Node impurity (how well the
trees partition the data at each step in the algorithm) is
measured using the Gini index [33].
Table 3 Results of Algorithm Models. Results of Optimized Algorithm Models (Training Set)
Biomarker Algorithm 33 Algorithm 21 LCDT1 Algorithm
SE (95% CI) 92.8% (87.9, 96.1%) 97.4% (92.0, 99.5%) 92.4% (89.2, 94.3%)
SP (95% CI) 97.2% (95.5, 98.8%) 98.3% (95.4, 99.5%) 96.9% (95.2, 98.0%)
The LCDT1 algorithm was developed with slight modifications using a smaller subset of biomarkers from the 21. This information is proprietary and a patent
application was filed
Fig. 1 Validation Test Result
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Due to the naturally occurring relationships between
the biomarkers examined, depending on variable’s im-
portance as the sole factor in determining if a biomarker
should stay in the smaller set of biomarkers to develop
the new model, is not viable. If any two biomarkers are
highly correlated, then the ‘importance’ of one bio-
marker is masked by the other biomarker. This is be-
cause both biomarkers would provide the same
information to the model thereby making the excluded
biomarker redundant. Therefore the ‘redundant’ bio-
marker, seeming insignificant, could have served as a
substitute for the included biomarker [34].
However, if the two biomarkers are statistically corre-
lated, but only one is biologically related to the disease,
we may not be able to determine which biomarker is
truly more important to the underlying biological mech-
anisms. Thus, biological relevance and patterns weighed
heavily.
Many of the markers in our set have been studied for
decades and have been shown to have potential for diag-
nosing LC [35–39]. In our studies, certain biomarkers
were elevated at higher levels or depressed depending on
whether we were looking at early stage (I-II) or late stage
(III-IV) NSCLC patients, e.g., the upregulation of CEA
and CYFRA-21-1 (common cancer markers widely stud-
ied) [36] were not as prominent in early stage NSCLC.
The occurrence of a lower expressed CYFRA in the early
stages of NSCLC has been indicated by Guergova-Kuras
M, et al. [37] using monoclonal antibodies to detect
early stage NSCLC. This phenomenon of varying marker
levels at different stages of NSCLC is not surprising as
protein abundance reflects current physiological state of
the disease.
Examples of the markers that were elevated in stage I-
II NSCLC were IL-8, MMP-9, and SAA. The synergistic
regulation and pathways of these markers correlates with
previous scientific findings: For example, IL-8 is a multi-
functional chemokine that induces chemotaxis and
phagocytosis, promotes angiogenesis, and aids in main-
tenance of mesenchymal features in carcinoma cells [40,
41]. Robust upregulation of CXCL8 (aka IL-8) has been
observed in erlotinib-resistant cell lines [41] which also
makes it a cancer therapy target. A study by Liu et al.
using 141 NSCLC patients indicated that IL-8 may have
up-regulated MMP-9 in lymph node metastasis of
NSCLC patients [38].
MMP-9 is a widely studied protease that cleaves extra-
cellular matrix (ECM) proteins to regulate ECM remod-
eling [42]. MMP-9 is involved in basement membrane
degradation that furthers tumor invasion and metastases
[42]. Past studies showed that MMP-9 s are highly ele-
vated in LC patients, especially stage III-IV [43, 44]. We
also observed a correlation between IL-8 and MMP-9
levels in LC patients.
SAA is an apolipoprotein that is secreted during acute
phase inflammation and is a known LC biomarker. Sung
et al. measured 180 healthy and 170 lung adenocarcin-
oma plasma or serum samples and found a 14-fold in-
crease of SAA levels in the LC patient [45]. Another by
Biaoxue, R. et al. indicated that SAA alone could detect
LC with 0.59 sensitivity and 0.92 specificity [39]. We
measured a six-fold increase in SAA levels at all stages
of NSCLC compared to healthy controls.
Proteins such as IL-8, MMP-9, and SAA are involved
in physiological inflammatory processes. Some of these
proteins are highly expressed in specific cancers, while
others are inhibited. Independently, each protein has the
ability of discriminating healthy from disease patients.
When LC biomarkers are multiplexed and combined
with an algorithm and additional demographic data, its
diagnostic capability increases and could serve as a
powerful clinical tool.
Table 4 Blind Test Performance for the 33, 21, and LCDT1 Algorithm (Validation Set)
Model
Statistics Algorithm 33 Algorithm 21 LCDT1 Algorithm
Accuracy 95.6% (92.4, 97.7%) 94.3% (90.7, 96.8%) 95.6% (92.4, 97.7%)
Sensitivity 89.1% (78.9, 95.3%) 89.1% (78.9, 95.3%) 89.1% (78.9, 95.3%)
Specificity 97.7% (94.6, 99.2%) 96.0% (92.2–98.2%) 97.7% (94.6, 99.2%)
Positive Predictive Value (PPV) 92.5% (83.0, 97.4%) 87.5% (77.0, 94.2%) 92.5% (83.0, 97.4%)
Negative Predictive Value (NPV) 96.6% (93.1, 98.6%) 96.5% (93.0, 98.5%) 96.6% (93.1, 98.6%)
NSCLC Prevalence 24.1% 24.1% 24.1%
True Positive (TP) 49 44 49
True Negative (TN) 169 166 169
False Positive (FP) 4 6 4
False Negative (FN) 6 7 6
All entries show the statistical (95% CI). *Other cancer types were included in the analysis. Each subject consisted of two replicates (N = 2) or two data points
processed by the algorithm. If one data point was positive, then the subject was considered positive for LC. Table was generated using R Version 3.4.4
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Using biomarkers for diagnosing diseases requires
constant revalidation to ensure that it remains applicable
to the intended population. Like any method, bio-
markers have limitations as they are affected by sample
origin, ethnicity, gender, environmental and carcinogenic
exposure, and reagent and platform variations. Strict
quality assurance and processes from the bench (e.g., de-
veloping reagents) to the clinic (e.g., collecting samples)
Fig. 2 ROC/AUC Curves. a. ROC/AUC Curves with other cancers types included. b. ROC/AUC Curves with only NSCLC cancers. Figures were
generated using R version 3.4.4
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Table 5 Median Biomarker Concentrations and P-Value Using the Training Set
Biomarker NSCLC Median [Q1-Q3], pg/mL Asthma, Smokers, Non-Smokers Median [Q1-Q3], pg/mL P-Value
CA125 26.4
[13.7–41.7]
13.6
[6.9–36.7]
0.073
CEA 2884.4
[1815.9–5573.8]
2115.3
[1194.8–3242.2]
0.003
CXCL9-MIG 4378.2
[2604.0–6844.5]
908.0
[539.0–1965.8]
< 0.001
CYFRA-21-1 5354.8
[3429.5–8090.4]
5088.3
[2939.9–9770.1]
0.026
GRO 2890.0-
[2076.9–4178.0]
874.4
[507.5–1790.2]
< 0.001
HGF 869.4
[643.9–1647.1]
476.3
[271.9–1177.1]
0.006
IL-10 22.8
[11.7–38.2]
23.8
[14.0–45.8]
0.525
IL-12p70 21.1
[15.5–27.0]
19.9
[16.5–127.4]
0.082
IL-16 693.6
[345.1–1458.7]
717.5
[298.8–1469.4]
0.902
IL-2 11.5
[10.9–16.6]
33.8
[19.7–52.1]
0.005
IL-4 41.7
[25.3–51.6]
33.3
[22.5–50.3]
0.902
IL-5 17.9
[15.7–23.5]
28.7
[12.8–46.8]
0.188
IL-7 10.6
[10.6–10.6]
34.9
[18.9–61.1]
NA
IL-8 126.3
[44.5–323.8]
23.6
[15.9–42.3]
< 0.001
IL-9 11.9
[11.0–20.7]
22.3
[15.2–42.6]
0.016
Leptin 30,408.0
[16,682.6–45,886.3]
22,190.7
[8684.4–54,863.7]
0.224
LIF 45.5
[30.5–79.3]
39.6
[27.1–82.3]
0.511
MCP-1 530.2
[391.363–721.512]
372.8
[279.7–462.0]
< 0.001
MIF 865.6
[453.6–1501.3]
395.0
[196.7–1274.8]
0.752
MMP-7 1978.3
[1184.2–3190.33]
3585.2
[2671.9–5080.6]
< 0.001
MMP-9 93,587.2
[62,827.2–124,300.6]
12,593.8
[8856.8–19,799.6]
< 0.001
MPO 353,987.8
[246,376.2–616,739.2]
117,658.8
[69,768.5–212,726.3]
< 0.001
NSE 7273.5
[3852.3–10,487.8]
6576.1
[3806.6–46,981.4]
< 0.001
PDGF AB/BB 25,169.6
[21,611.8–30,055.0]
41,800.6
[26,115.3–53,016.0]
< 0.001
RANTES 105,356.2
[79,497.9–155,040.2]
38,458.4
[23,423.8–112,641.5]
0.003
Resistin 35,145.6
[25,185.8–53,466.7]
12,966.2
[9521.2–17,533.1]
< 0.001
SAA 6.55e7
[2.52e7–1.2e8]
8.5e6
[4.175e6–1.9825e7]
< 0.001
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to the acquisition of the end result (e.g., data cleaning
and processing) are imperative. Furthermore, statistical
and machine learning algorithms also need to be tested
for bias and refined as new data are collected.
Despite, these limitations, biomarkers in conjunction
with machine learning methods serve as an important
component in fighting cancer as they provide benefits.
Such advantages include a means of a simple, non-
invasive method in detecting cancer; acquiring prognos-
tic information, and assessment of the efficacy of thera-
peutic methods.
Conclusions
We aimed to develop an accurate test that was specific
to early stage NSCLC. A multi-cancer test, though re-
markable, could increase patient anxiety and fiscal ex-
pense due to additional (possibly unnecessary) follow-up
procedures. These concerns are mirrored in medical
practitioners’ reluctance to order full body imaging in
asymptomatic patients [46].
This study shows that we were able to successfully re-
duce the number of biomarkers from 33 to 21, while
maintaining a high performance in detecting early stage
NSCLC. The LCDT1 is 97.7% specific for Stage I
NSCLC even when other cancer types were present. An
estimated 9 out of 10 (89.1% sensitive) early stage LC
patients would be detected by the LCDT1. The LCDT1
is 95.6% accurate.
As a diagnostic test, physicians prefer tests with high
sensitivity and sacrifice specificity. The argument is that
not detecting “a” cancer is more detrimental than a false
negative. A highly sensitive diagnostic test is important
where the test is used to identify a serious but treatable
disease; and a highly specific test avoids further subjec-
tion of the patient to unnecessary follow-up medical
procedures. In the case of LC, current diagnostic
methods (i.e., CT, PET) have high sensitivity but low
specificity. If patients who are suspected to have a lung
nodule on a CT are given a second test with a low (or
high) sensitivity and high specificity, then nearly all of
the false positives could be identified as disease free.
Our clinical goal is to decrease risks and unnecessary
procedures to patients without delaying curative treat-
ment [47] and increase access to communities with so-
cial and economic barriers. The LCDT1 is a simple
blood test with great potential for clinical applications in
detecting Stage I NSCLC. When used with gold stan-
dards such as the CT/PET scans in conjunction with al-
gorithms and improved PN guidelines, could mean a
significant reduction in the number of false negatives
and an increase in early stage detection.
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< 0.001
sFasL 229.8
[78.2–498.2]
263.7
[135.9–573.4]
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